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Abstract Using acridine orange as a reporter compound, we 
demonstrate that suramin enters and accumulates in low pH 
intracellular compartments (endosomes, lysosomes, and trans-
Golgi complex) of normal and v-sis-transformed NIH 3T3 cells. 
The concentration of suramin in these acidic compartments is 
estimated to be > 150 μΜ, higher than the concentration known 
to completely inhibit interaction of the platelet-derived growth 
factor (PDGF) receptor and v-sis gene product. These results 
support the hypothesis that suramin reverses the transformed 
phenotype of v-sis-transformed cells by entering the cell via 
endocytosis and blocking interaction of the v-sis gene product 
and PDGF receptor in intracellular organdies. 
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1. Introduction 
Suramin is an antiparasitic, antiviral and anticancer agent 
[1-10]. It inhibits the activities of many cytoplasmic and nu-
clear enzymes in vitro [11-14], but the significance of these 
effects in the mode of suramm action remains uncertain due to 
the fact of very poor permeability of suramin in the plasma 
membrane [1]. Suramin inhibits interactions between growth 
factors and their receptors [15-25] and reverses the trans-
formed phenotype of v-sis-transformed cells [17]. Suramin 
was reported to reverse the transformed phenotype of v-sis-
transformed cells by blocking the v-sis gene product/PDGF 
receptor interactions at the cell surface [26,27]. In previous 
reports [28,29], we showed that suramin treatment of v-sis-
transformed cells inhibited intracellular turnover of both 
platelet-derived growth factor (PDGF) receptor and v-sis 
gene product by blocking their interaction in the endoplasmic 
reticulum (ER) and Golgi complex. Together with other ob-
servations, these results led us to suggest that suramin reverses 
the transformed phenotype of v-sis-transformed cells by enter-
ing the cell via endocytosis and inhibiting the interaction of 
the PDGF receptor and v-sis gene product in intracellular 
organelles such as trans-Golgi complex [28,29]. To further 
define the intracellular action of suramin, we examined the 
subcellular localization of suramin following treatment of cells 
with this drug. Using acridine orange as a reporter, we dem-
onstrate here that suramin accumulates in the acidic intracel-
lular compartments following treatment of acridine orange-
preloaded v-sis-transformed NIH 3T3 cells with suramin. 
These results are consistent with the hypothesis that suramin 
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blocks the intracellular interaction of the v-sis gene product 
and PDGF receptor in v-sis-transformed cells [28,29]. 
2. Materials and methods 
2.1. Materials 
Suramin was obtained from FBA Pharmaceuticals (West Haven, 
CT). Acridine orange was obtained from Sigma Chemical Company 
(St. Louis, MO). 4-Methylumbelliferyl (4-MU) ß-D-glucuronide was 
obtained from Research Products International (Elk Grove, IL), v-sis-
transformed (simian sarcoma virus-transformed) NIH 3T3 and NRK 
(normal rat kidney) cells were kindly provided by Drs. Stuart A. 
Aaronson and Keith C. Robbins, National Cancer Institute, v-sis-
transformed NIH 3T3, v-sis-transformed NRK, NIH 3T3, Swiss 
mouse 3T3 and NRK cells were routinely cultured in Dulbecco's 
modified Eagle's medium (DMEM) containing 10% fetal calf serum. 
2.2. Measurement of acridine orange fluorescence in the presence of 
various concentrations of suramin 
The reaction mixture contained 1 μΜ acridine orange and various 
concentrations of suramin as indicated in 0.2 M sodium phosphate 
buffer (pH 7.4), 0.2 M sodium phosphate buffer (pH 6.5), or 0.2 M 
sodium acetate buffer (pH 5.0). The fluorescence emission of the re-
action mixture was scanned from 500 nm to 575 nm using the exci-
tation wavelength at 480 nm. 
2.3. Suramin treatment of acridine orange-preloaded cells 
Cells were grown on coverslips for one day in DMEM containing 
10% fetal calf serum. Cells were washed with serum-free DMEM and 
incubated with 1 μΜ acridine orange in serum-free DMEM at 37°C 
for 30 min. The acridine orange-preloaded cells were washed and 
treated with various concentrations of suramin at 37°C for the indi-
cated time periods. The cells were then viewed and photographed with 
a Leitz Orthoplan fluorescence microscope. 
2.4. Measurement of ß-glucuronidase activity in the medium of 
suramin-treated v-sis-transformed NIH 3T3 cells 
Cells grown on 35 mm Petri dishes were treated with and without 
21 μΜ suramin in serum-free DMEM at 37°C for 1 h. The ß-glucur-
onidase activity in the conditioned medium was assayed using 4-meth-
ylumbelliferyl ß-D-glucuronide as substrate according to the procedure 
of Brot et al. [30]. 
3. Results and discussion 
Acridine orange is a non-invasive fluorescent compound 
which has been used to examine the luminal pH of intracel-
lular organelles in many cell types including fibroblasts [31]. It 
accumulates in low pH intracellular compartments such as 
endosomes, lysosomes, trans-Golgi complex and exocytic 
vesicles [31]. The accumulation of acridine orange is depend-
ent on the luminal pH of these acidic compartments. The 
more acidic the compartments are, the more acridine orange 
accumulates [31]. The concentration of acridine orange deter-
mines the color of fluorescence emitted [31,32]. An orange-red 
color is seen in vesicles of low pH such as lysosomes and late 
endosomes, whereas a yellow to orange-red color is seen in 
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organelles of high pH (pH 6.0-6.5) such as trans-Golgi com-
plex and exocytic vesicles (Fig. 1) [31]. 
Acridine orange is a weak base and polyaromatic com-
pound and complexes with suramin possibly through stacking 
and electrostatic interactions. To examine this interaction, we 
investigated the effect of various concentrations of suramin on 
the fluorescence of acridine orange. As shown in Fig. 2A, 
increasing concentrations of suramin progressively diminished 
the intensity of fluorescence of acridine orange. The maximal 
effect of suramin was observed at a molar ratio of ~ 1 : 3 
(suramin:acridine orange) in the range of pH 5.0 to 7.4 
(Fig. 2B). This molar ratio of suramin-acridine orange com-
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Fig. 2. Fluorescence spectra of acridine orange in the presence of 
various concentrations of suramin (A) and pH effect of suramin-
quenching of acridine orange fluorescence (B). A: The reaction mix-
ture contained 1 μΜ of acridine orange and various concentrations 
of suramin in 0.2 M sodium phosphate buffer (pH 7.4). The fluores-
cence emission of the reaction mixture was scanned from 500 nm to 
575 nm using the excitation wavelength at 480 nm. The fluorescence 
spectrum of acridine orange revealed a peak at 530 nm. B: The re-
action mixture contained 1 μΜ acridine orange and various concen-
trations of suramin in 0.2 sodium phosphate buffer, pH 7.4, 0.2 M 
sodium phosphate buffer, pH 6.5 or 0.2 M sodium acetate buffer, 
pH 5.O. The relative fluorescence intensity of the reaction mixture 
was measured at 530 nm of fluorescence emission. The relative fluo-
rescence intensity of the reaction mixture without suramin was tak-
en as 100%. Increasing concentrations of suramin diminished the 
fluorescence of 1 μΜ acridine orange, reaching a maximal at a ratio 
of ~1:3 (suramin:acridine orange). 
plex, which is constant at least up to 800 μΜ of acridine 
orange, is essentially identical with that reported for the com-
plex of suramin and 4',4"-bis (1,4,5,6-tetrahydro-2-pyrimidin-
yl) terephthalanilide (a weak-base aromatic compound analo-
gous to acridine orange) [33]. These results show that acridine 
orange can be used as a reporter compound for probing the 
entry of suramin into acidic intracellular compartments. 
To examine the subcellular localization of suramin, NIH 
3T3 cells were preloaded with 1 μΜ of acridine orange at 
37°C for 30 min. The acridine orange-preloaded cells were 
then treated with various concentrations of suramin at 37CC. 
After 1 h, the cells were then examined with a fluorescence 
microscope. As shown in Fig. 3, the control cells (without 
suramin) showed yellow to orange-red fluorescence. However, 
suramin treatment resulted in the disappearance of yellow to 
orange-red fluorescence in these cells. At 21 μΜ concentra-
tion, suramin almost completely abolished the yellow to or-
Fig. 1. Acridine orange fluorescence in normal NIH 3T3 cells. Nor-
mal NIH 3T3 cells were treated with 1 μΜ acridine orange as de-
scribed in the text. The bright orange-red fluorescence at the distal 
ends represents lysosomes and late endosomes. The yellow to or-
ange-red fluorescence at the perinuclear region represents exocytic 
vesicles and trans-Golgi complex [31,32]. 
Fig. 4. Reversibility of the suramin-quenching effect on the distinct 
fluorescence in acidic intracellular compartments of acridine orange-
preloaded v-sis-transformed NIH 3T3 cells, v-sis-transformed NIH 
3T3 cells were incubated with 1 μΜ acridine orange in DMEM at 
37CC for 30 min. The acridine orange-loaded cells were then treated 
without (A) or with (B) 21 μΜ suramin in DMEM at 37°C for 1 h. 
The cells were then incubated in DMEM without suramin at 37°C 
for 1.5 h (C) and finally further incubated with 1 μΜ acridine or-
ange in DMEM at 37°C for 30 min (D). 
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Fig. 3. Disappearance of the distinct fluorescence in acidic intracellular compartments of acridine orange-preloaded NIH 3T3 cells following 
treatment with suramin. NIH 3T3 cells were incubated with 1 μΜ acridine orange in DMEM at 37°C for 30 min. After washing, the acridine 
orange-loaded cells were treated with 0, 7, 21 and 35 μΜ of suramin in DMEM at 37°C for 1 h. The cells were then washed and photographed 
under a Leitz Orthoplan fluorescence microscope. The black background shown in the control (0 μΜ suramin) is due to color filtration, which 
was used to enhance the yellow to orange-red color. 
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ange-red fluorescence. It is of interest to note that this optimal 
concentration of suramin (21 μΜ) was very close to the con-
centration of suramin (25 μΜ) required to block the turnover 
of the PDGF receptor in the Golgi complex of v-sis-trans-
formed cells [28,29]. Similar results were also observed in v-
sis-transformed NIH 3T3, NRK (normal rat kidney), v-sis-
transformed NRK, and Swiss mouse 3T3 cells. 
The concentration of acridine orange in acidic intracellular 
compartments is believed to exceed 500 μΜ at which yellow 
to orange-red fluorescence is observed [31,32]. Since suramin 
quenches the fluorescence of acridine orange by forming a 3:1 
(mole:mole) complex (Fig. 2B) and since the treatment of cells 
with suramin results in virtually complete abolishment of yel-
low to orange-red fluorescence in the acidic intracellular com-
partments (Fig. 3), it is estimated that the minimal concen-
tration of suramin in these acidic compartments is > 150 μΜ. 
This exceeds the concentration required for complete inhibi-
tion of the interaction between the cell-surface PDGF recep-
tor and v-sis gene product (or PDGF) [15,16]. 
In order to exclude the possibility that the observed alter-
ation in fluorescence might be due to the suramin toxicity 
(damage to organelles), we examined the reversibility of the 
suramin effect, v-sis-transformed NIH 3T3 cells preloaded 
with acridine orange as described above, were treated with 
or without 21 μΜ suramin. After 1 h at 37°C, suramin was 
removed. The cells were then incubated with medium in the 
absence of suramin for 1.5 h and finally reloaded with 1 μΜ 
acridine orange. As illustrated in Fig. 4B, suramin treatment 
abolished the orange-red fluorescence when compared with 
control (Fig. 4A). It is of importance to note that suramin 
treatment did not affect the intensity of blue fluorescence in 
the cytoplasm. After a 1.5 h chase in the medium without 
suramin, the orange-red fluorescence gradually reappeared 
(Fig. 4C). Reloading of acridine orange completely restored 
the orange-red fluorescence in these cells (Fig. 4D). These 
results suggest that the suramin effect is reversible and not 
mediated by cellular toxicity. 
As previously described, the accumulation of acridine or-
ange in intracellular organelles is dependent on their luminal 
pH. Suramin might raise the pH of these acidic compartments 
by depletion of ATP or by inhibition of the proton pump 
without direct entry into these organelles. We investigated 
this possibility by measuring the release of the lysosomal en-
zyme ß-glucuronidase into the medium. Elevation of the pH 
of acidic organelles is known to cause newly synthesized lyso-
somal enzymes to be rerouted from the lysosomal to a secre-
tory pathway [34]. Suramin treatment did not augment the 
concentration of ß-glucuronidase in the medium (data not 
shown), suggesting that suramin did not affect the luminal 
pH of acidic intracellular compartments. 
Suramin appears to be unable to enter cells by directly 
passing through hydrophobic plasma membranes because it 
possesses strongly hydrophilic polysulfonate groups [1]. This 
is supported by the observation that suramin treatment did 
not alter the intensity of blue fluorescence in the cytoplasm 
(Fig. 4). Because of its polysulfonate and polyaromatic 
groups, suramin can bind through electrostatic and hydropho-
bic interactions to a variety of proteins including membrane 
proteins. This suggests that suramin possibly enters the cell 
through endocytosis mediated by clathrin-coated and/or non-
clathrin-coated vesicles following its binding to plasma mem-
brane proteins. At the concentration (21 μΜ) in the medium, 
suramin is able to accumulate in the acidic intracellular com-
partments to reach > 150 μΜ. At > 150 μΜ, suramin is 
capable of blocking the interaction of the PDGF receptor 
and v-sis gene product in the trans-Golgi complex as previ-
ously reported [28,29]. 
This communication provides the first semiquantitative 
measurement of suramin accumulation in acidic intracellular 
compartments. These results pave the way for examination of 
the real-time kinetics of suramin entry into cells by optical 
(video camera) methodology. 
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